Ruth Salmon
About Ruth Salmon
Ruth Salmon is the Vice President of Preclinical Sciences at Bristol Myers Squibb, specializing in Cellular Therapy and Immune Oncology with over 20 years of experience in preclinical sciences and immunology.
Title: Vice President, Preclinical Sciences
Ruth Salmon currently serves as the Vice President of Preclinical Sciences at Bristol Myers Squibb. Based in Seattle, Washington, she provides leadership in the preclinical sciences field, particularly focusing on Cellular Therapy and Immune Oncology. She has been with the company since November 2019.
Company: Bristol Myers Squibb
Ruth Salmon is employed at Bristol Myers Squibb in Seattle, Washington. In her role as Vice President of Preclinical Sciences, she leverages her extensive experience and expertise to drive advancements in the fields of Translational Immunology and Preclinical Pharmacology. Her efforts contribute significantly to the company’s research and development initiatives in cellular therapy and immune oncology.
Previous Roles at Celgene and Juno Therapeutics
Before joining Bristol Myers Squibb, Ruth Salmon held significant roles at Celgene and Juno Therapeutics. At Celgene, she served as Senior Director of Preclinical Development from 2018 to 2019 in Seattle. Prior to that, she worked at Juno Therapeutics, Inc. as a Senior Director from 2015 to 2018, also in Seattle. Her work at these companies further solidified her expertise in immunology and preclinical sciences.
Career at Novo Nordisk and VLST Corp
Ruth Salmon's career includes leadership positions at Novo Nordisk and VLST Corp. She was the Team Leader for Translational Immunology at Novo Nordisk from 2013 to 2014 in Seattle, WA. Prior to that, she spent five years at VLST Corp as Associate Director of Immunology and Preclinical Pharmacology from 2007 to 2012. Her roles at these companies involved significant contributions to preclinical research and immunology.
Early Career at QLT Inc.
Ruth Salmon’s early career was marked by her role at QLT Inc., where she served as Manager of Preclinical Development from 2000 to 2007. During her seven-year tenure at QLT Inc., she honed her skills in preclinical sciences, laying a solid foundation for her subsequent leadership roles in the biotech and pharmaceutical industry.